Male | Female | |||||||
---|---|---|---|---|---|---|---|---|
All | SC | HC | p | All | SC | HC | p | |
No | 27 | 16 (59.3%) | 11 (40.7%) | 29 | 16 (37.2%) | 13 (30.2%) | ||
Age (years) | 53 (49–58) | 55 (51–59) | 51 (48–54) | 0.373 | 52 (46–60) | 54 (47–62) | 49 (44–59) | 0.496 |
BMI (kg/m2) (n = 16) | 26.4 (25.4–30.6) | 25.6 (24.2–26.9) | 26.4 (25.8–30.8) | 0.441 | 22.9 (21.1–25.7) | 23.0 (20.2–27.8) | 22.8 (21.3–24.4) | 0.999 |
Smoker (n = 9) | – | – | ||||||
Never | – | – | 3 (33.3%) | – | – | 8 (61.5%) | ||
Previous (> 6 months) | – | – | 5 (55.6%) | – | – | 2 (15.4%) | ||
Current | – | – | 1 (11.1%) | – | – | 3 (23.1%) | ||
Route of transmission (n = 3) | – | – | ||||||
Intravenous drug user | – | 3 (100.0%) | – | – | 3 (50.0%) | – | ||
Medical and Aesthetic procedures | – | 0 (0.0%) | – | – | 2 (33.3%) | – | ||
Work accident | – | 0 (0.0%) | – | – | 1 (16.7%) | – | ||
Time from clearance (years) (n = 14) | – | 2.3 (1.3–3.8) | – | – | – | 9.0 (4.0–28.0) | – | – |
IFN-λ4 genotype (rs12979860) | 0.589 | 0.363 | ||||||
CC | 17 (63.0%) | 11(68.8%) | 6 (54.5%) | 15 (53.6%) | 8 (53.3%) | 7 (53.8%) | ||
CT | 7 (25.9%) | 4 (25.0%) | 3 (27.3%) | 11 (39.3%) | 5 (33.3%) | 6 (46.2%) | ||
TT | 3 (11.1%) | 1 (6.2%) | 2 (18.2%) | 2 (7.1%) | 2 (13.3%) | 0 (0.0%) | ||
Stage of liver fibrosis (n = 3) | – | – | ||||||
F0 | – | 1 (33.3%) | – | – | 0 (0.0%) | – | ||
F1 | – | 2 (66.7%) | – | – | 5 (83.3%) | – | ||
F2 | – | 0 (0.0%) | – | – | 1 (16.7%) | – | ||
F3 | – | 0 (0.0%) | – | – | 0 (0.0%) | – | ||
F4 | – | 0 (0.0%) | – | – | 0 (0.0%) | – | ||
Liver markers | ||||||||
FIB4 (n = 21) | 1.2 (1.0–1.4) | 1.3 (1.2–2.0) | 1.0 (0.9–1.1) | 0.006 | 1.2 (0.9–1.5) | 1.5 (1.0–1.6) | 1.0 (0.8–1.2) | 0.038 |
APRI (n = 21) | 0.3 (0.2–0.4) | 0.4 (0.3–0.5) | 0.2 (0.2–0.3) | 0.020 | 0.3 (0.2–0.3) | 0.3 (0.2–0.4) | 0.2 (0.2–0.3) | 0.023 |
AST (mg/dL) (n = 25) | 24.0 (19.0–33.0) | 28.0 (24.0–38.5) | 19.0 (15.5–22.3) | 0.008 | 19.0 (16.0–24.0) | 21.5 (16.0–27.8) | 19.0 (15.0–20.0) | 0.187 |
ALT (mg/dL) (n = 26) | 27.0 (17.3–37.5) | 28.5 (22.5–40.8) | 19.0 (14.0–25.5) | 0.065 | 17.5 (13.8–25.0) | 19.0 (17.0–28.8) | 15.0 (11.8–17.5) | 0.053 |
GGT (mg/dL) (n = 25) | 28.0 (22.0–39.0) | 30.0 (22.0–56.0) | 28.0 (26.0–33.3) | 0.803 | 15.5 (11.0–34.0) | 19.5 (13.3–54.8) | 13.5 (10.8–17.8) | 0.148 |
Metabolic syndrome markers | ||||||||
TyG (n = 21) | 8.5 (8.2–8.7) | 8.5 (8.1–8.6) | 8.7 (8.4–8.9) | 0.173 | 8.2 (7.9–8.5) | 8.4 (8.3–8.7) | 8.1 (7.9–8.2) | 0.060 |
METS IR (n = 14) | 37.1 (33.7–46.0) | 33.7 (32.6–39.7) | 40.3 (36.8–46.0) | 0.454 | 28.1 (25.9–34.6) | 29.2 (24.4–36.1) | 28.0 (26.0–30.1) | 0.849 |